PBAC's latest decision on Bortezomib: Recommended (2022). Considered for Multiple myeloma. Listing of two new solution for injection forms (2.5 mg/mL and 3.5 mg/1.4 mL) under the Section 100 Efficient Funding of Chemotherapy Program.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
12
first 2006
Submissions
12
2006 → 2022
Eligible population
Patients with multiple myeloma requiring bortezomib therapy, eligible for treatment via intravenous or subcutaneous administration.
Therapy area
Oncology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
bortezomib 1 mg, 3 mg and 3.5 mg powder for injection
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. PBAC noted recommendation was on cost-minimisation basis with nil cost to Government.
ICER (historical)
$15k/QALY across 4 submissions (2006–2011) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.